RA Capital doubles down on Siddhartha Mukherjee's vision for a new cell engineering approach, leading Vor's $110M Series B
Vor Biopharma is muscling up.
CEO Robert Ang, who was reluctant to divulge the headcount when discussing his move from Neon Therapeutics to Vor …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.